SCHEMBL6939713

SCHEMBL6939713

CCCNS(=O)(=O)c1cc2c[c]c(=O)n(P(=O)(O)O)c2cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
GSTO1 P78417 2/20 0.32
LMNA P02545 1/20 0.31
RECQL P46063 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ATM Q13315 1/20 0.31
ALDH1A1 P00352 2/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7651605 0.94 CYP1A2 (0.36) POLBCA12CA9GSTO1SMN1; SMN2
SCHEMBL7652709 0.91 KDM4E (0.36) POLBATMALDH1A1GAAKMT2A
SCHEMBL7651550 0.89 GAA (0.40) POLBGSTO1RECQLNPSR1ALDH1A1
Bromide SCHEMBL6937197 0.88 GAA (0.39) POLBGSTO1RECQLNPSR1ALDH1A1
SCHEMBL6939753 0.85 KMT2A (0.34) GSTO1KMT2A
SCHEMBL7650678 0.85 ALDH1A1 (0.40) LMNASMN1; SMN2NPSR1ALDH1A1GAA
SCHEMBL7647530 0.84 CNR2 (0.33) CA12CA9
SCHEMBL7648790 0.82 POLB (0.30) POLB
SCHEMBL7652661 0.82 GSTO1 (0.37) GSTO1LMNANPSR1ATMALDH1A1
SCHEMBL7647454 0.80 THRB (0.32) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1125942-B1 Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-04-09 EP claimed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US claimed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US claimed
US-6486143-B2 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031746-A1 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds CA6, P2RY6, FPR3 POLB 2728/4885L3MBTL1 4403/4885CA12 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.